MK-7684A is a combination of two medications, Vibostolimab and Pembrolizumab, used together to help the body’s immune system fight cancer. This combination is being tested to see if it can help prevent melanoma, a type of skin cancer, from coming back after surgery. Vibostolimab is a type of drug that helps activate the immune system to attack cancer cells, while Pembrolizumab is already used to treat various cancers by blocking a pathway that cancer cells use to hide from the immune system.

Pembrolizumab is a medication that helps the immune system detect and fight cancer cells. It works by blocking a specific pathway that cancer cells use to avoid being attacked by the immune system. This medication is already used in treating several types of cancer, including melanoma, and is being tested in this trial to see how well it works compared to the combination of Vibostolimab and Pembrolizumab.

Melanoma – Melanoma is a type of skin cancer that originates in the melanocytes, the cells responsible for producing melanin, the pigment that gives skin its color. It often begins as a mole that changes in size, shape, or color, but it can also appear on skin that looks normal. As melanoma progresses, it can grow deeper into the skin and spread to other parts of the body, including lymph nodes and internal organs. The disease is known for its ability to metastasize, or spread, rapidly if not detected early. Melanoma can occur on any skin surface, but it is more common in areas exposed to the sun, such as the back, legs, arms, and face. Early detection and monitoring of changes in the skin are crucial in managing the progression of melanoma.